Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

StockBeat: AstraZeneca Gets a Booster Shot From Trump Report

Stock MarketsAug 24, 2020 11:10
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.

By Geoffrey Smith 

Investing.com -- Europe’s stock markets opened the week strongly, ostensibly on optimism about the rapid deployment of at least one vaccine to bring the Covid-19 pandemic under control.

The benchmark Stoxx 600 rose 1.7% to 371.24, a level that still leaves it nearly 2.5% below its post-pandemic high. In contrast to U.S. markets, which have regained momentum as a second wave of Covid-19 infections has faded, European stocks have plateaued in recent weeks as the reopening of the economy has prompted fears of another wave – even though infection rates have remained well below U.S. levels.

The Financial Times reported at the weekend that President Donald Trump is preparing to bypass normal drug authorization procedures to ensure that the vaccine being developed jointly by AstraZeneca (NYSE:AZN) and the University of Oxford can be made available before the U.S. elections on November 3rd.

The story came as the Food and Drug Administration issued emergency use authorization of convalescent plasma for treating Covid-19 patients. FDA Commissioner Stephen Hahn said that the measure isn’t a full approval and the agency hasn’t finished evaluating evidence as to its effectiveness and safety.

Trump on Sunday had vented on Twitter against ‘deep state’ interests at the Food and Drug Administration who he claimed were slowing down the approvals process in order to stop him getting re-elected.  It’s unclear who he was referring to. Hahn was appointed by Trump himself.

Either way, AstraZeneca’s stock in London got a predictable boost from the news, rising 3.1% on a day when Europe’s main indexes were all up by more than 1.5%.

But for AstraZeneca, as for many other pharma and biotech companies racing to develop a cure for the coronavirus, the market now seems inoculated against its own hype.

AstraZeneca’s stock peaked over a month ago, at a level nearly 7% higher. Italy’s DiaSorin (LON:0GZX) stock remains over 20% below its May peak, Biontech (F:22UAy) stock listed in Germany is almost 30% down from its peak in July, despite a steady stream of positive trial results for the drug it is developing together with Pfizer (NYSE:PFE). Moderna (NASDAQ:MRNA) stock in the U.S. is off 30%, not helped by the sight of company insiders heading for the exit within days of it dumping new shares on the public market, while Novavax (NASDAQ:NVAX) stock is languishing 24% below its peak.

In most of these cases, share prices peaked within days of July 16, when the U.S. hit what is – so far- its highest daily number of new infections at over 77,000. As confidence has grown that there will be no return to generalized lockdowns, the premium that the market has put on vaccine has fallen.

By that logic, the stocks could all rebound smartly if the reopening of schools in Europe and North America, combined with the onset of colder weather, turn case numbers higher again.

But the sector could live to rue the overt politicization of the drug approval process in the longer term. A poll by Yahoo and YouGov last month indicated that only 40% of U.S. adults would definitely take a vaccine that was approved in the current circumstances.

The risk of approving a vaccine that is either ineffective, or downright unsafe, is arguably small, but it is very clearly real. That would be a disaster as regards the containment of Covid-19. But discrediting the principle of vaccination, at a time when it is already under threat from so much unfounded conspiracy theory, would carry untold risks for public health for years to come.

StockBeat: AstraZeneca Gets a Booster Shot From Trump Report
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
ger ber
ger ber Aug 24, 2020 14:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nice promotion for astrazeneca- trump lol
ger ber
ger ber Aug 24, 2020 14:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Well I can‘t see anyone in its right sense using Astrazeneca after its last resort to msnufacture this vaccine but where is the problem oxford
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email